Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Carparts.Com Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.55 (market cap $29.60B), while Carparts.Com Inc trades at $6.34 (market cap $51.67M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 572.9× Carparts.Com Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PRTS | |
|---|---|---|
Market Cap | $29.60B | $51.67M |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $11.40 |
52-Week Low | $205.48 | $3.88 |
Enterprise Value | $27.56B | $66.64M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
CarParts.com (PRTS) trades at $6.32, down 6.37% today, with a bullish technical signal despite negative profitability metrics. The company has beaten earnings expectations for three consecutive quarters, though revenue has declined from $676M in 2023 to $548M in 2025. Recent developments include a 10:1 reverse stock split completed in May 2026 and a new $25M credit facility, while analyst consensus remains positive with 60% buy ratings.
The outlook is mixed: technical indicators and analyst sentiment suggest potential upside, but fundamental challenges persist with negative net income margins and cash flow concerns. Key risks include ongoing operational losses and competitive pressures in the auto parts e-commerce space, requiring careful monitoring of the company's turnaround execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
